{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015708","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.506705+00:00","generated_at":"2026-05-30T00:33:11.394769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)","bullets":["Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.","Cash $60.0M at Sep 30, 2024 (from $117.5M Dec 2023); received $5M milestone from Gilead for HB-500 dosing.","Phase 2 eseba-vec + pembrolizumab in HPV+ HNSCC enrolled 68 patients ahead of schedule; updated data at SITC 2024.","First patients dosed in MSKCC Investigator Initiated Trial of eseba-vec as adjuvant therapy for HNSCC.","Leadership: Malte Peters appointed CEO, Terry Coelho CFO in July; reverse stock split effected 1:10."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015708","json":"https://secwatch.observer/filing/0001558370-24-015708.json","markdown":"https://secwatch.observer/filing/0001558370-24-015708.md","text":"https://secwatch.observer/filing/0001558370-24-015708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024015708/0001558370-24-015708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024015708/hook-20241114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:33:11.394769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}